Session

Diagnosing TCC - has the cystoscope had its day?

Poster Session 59

  • Location:
    Room Stockholm (Hall B2, level 0)
  • Chairs:
     R.T. Bryan, Birmingham (GB)
     A. Miernik, Freiburg (DE)
     L-P. Xie, Hangzhou (CN)
  • Aims and objectives of this session

    Understand the potential of innovations in endoscopy and urine-based diagnostics.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
738
The feasibility and safety evaluation of the pressure monitored air cystoscopy during active hematuria

By: Yu F., Yao L., Wang Y., Yu W., Zhang Q., Wu S., Zhang X., He Z., Zhou L., Jin J.

Institutes: Peking University First Hospital, Dept. of Urology, Beijing, China

739
Comparison of white light, photodynamic diagnosis (PDD) and narrow band imaging (NBI) in detection of flat dysplasia and CIS at transurethral resection of the bladder – the DaBlaCa-8 study

By: Drejer D.1, Beji S.2, Lam G.W.2, Jensen J.B.1

Institutes: 1Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, 2Herlev Hospital, Dept. of Urology, Herlev, Denmark

740
A new compound for photodynamic diagnosis of non-muscle invasive bladder cancer – results of a multi-centre phase 2 study with PVP-Hypericin

By: Straub M.1, Steiner R.2, Schiefelbein F.3, Garlonta V.4, Deger S.5, Lusuardi L.6, Von Pokrzywnitzki W.7, Knüchel R.8, Schmidbauer J.9

Institutes: 1Klinikum Rechts der Isar der Technischen Universität Muenchen, Dept. of Urology, Munich, Germany, 2Sindelfingen-Böblingen Medical Centre, Dept. of Urology, Sindelfingen, Germany, 3Missionsaerztliche Klinik, Dept. of Urology, Würzburg, Germany, 4Community Hospital Karlsruhe, Dept. of Urology, Karlsruhe, Germany, 5Paracelsus Krankenhaus Ruit, Dept. of Urology, Ruit, Germany, 6Paracelsus Medical University, Dept. of Urology, Salzburg, Austria, 7Vivantes Klinikum Am Urban, Dept. of Urology, Berlin, Germany, 8University Hospital RWTH, Dept. of Pathology, Aachen, Germany, 9Medical University of Vienna, Vienna General Hospital, Dept. of Urology, Vienna, Austria

741
Does hexaminolevulinate detect chromosomal aberrations in the false-positive bladder biopsies?

By: D’Andrea D.1, Martini T.2, Mian C.3, Palermo S.M.1, Comploj E.1, Pycha A.1

Institutes: 1General Hospital of Bolzano, Dept. of Urology, Bolzano, Italy, 2Ulm University Medical Center, Dept. of Urology, Ulm, Germany, 3General Hospital of Bolzano, Dept. of Pathology, Bolzano, Italy

742
Urothelial tumor and dual band imaging: New concept in confocal laser endomicroscopy

By: Bonnal J.L.1, Yakoubi R.1, Rock A.1, El Maadarani K.1, Marien A.1, Mauroy B.1, Gosset P.2

Institutes: 1Hôpital Saint-Philibert, Dept. of Urology, Lomme Cedex, France, 2Hôpital Saint-Vincent, Dept. of Anatomopathology, Lille Cedex, France

743
Measuring the depth of tumor invasion may have greater prognostic value than AJCC/UICC staging of bladder cancer

By: Nishikimi T.1, Tsuzuku T.2, Mori Y.3, Kashiwagi Y.4, Sassa N.5, Kimura T.6, Fukatsu A.7, Tanaka K.8, Hattori R.9, Takahashi S.3, Gotoh M.5

Institutes: 1Nagoya Daini Red Cross Hospital, Dept. of Urology, Nagoya, Japan, 2Nagoya Daini Red Cross Hospital, Dept. of Pathology, Nagoya, Japan, 3Nagoya City University, Dept. of Pathology, Nagoya, Japan, 4Okazaki Municipal Hospital, Dept. of Urology, Okazaki, Japan, 5Nagoya University, Dept. of Urology, Nagoya, Japan, 6JCHO,Cyukyo Hospital, Dept. of Urology, Nagoya, Japan, 7Komaki Municipal Hospital, Dept. of Urology, Komaki, Japan, 8Komaki Municipal Hospital, Dept. of Urology, Kariya, Japan, 9Nagoya Daiichi Red Cross Hospital, Dept. of Urology, Nagoya, Japan

744
Indolent clinical outcomes of carcinoma in situ-associated pTa bladder tumour after bacillus Calmette-Guérine: Need for a new classification of carcinoma in situ

By: Kim S.J.1, Hong S.2, Kim H.J.2, You D.1, Jeong I.G.1, Song C.1, Hong B.S.1, Kim C.S.1, Ahn H.1, Hong J.H.1

Institutes: 1Asan Medical Center, Dept. of Urology, Seoul, South Korea, 2Dankook University College of Medicine, Dept. of Urology, Cheonan, South Korea

745
Prognostic performance of different pathological grading schemes in non-muscle invasive transitional-cell carcinoma

By: Nabebina T.2, Rolevich A.1, Dubrouski A.2, Polyakov S.1, Krasny S.1

Institutes: 1N.N.Alexandrov National Cancer Centre, Dept. of Urology, Minsk, Belarus, 2N.N.Alexandrov National Cancer Centre, Dept. of Pathology, Minsk, Belarus

746
Molecular tumour grading of non muscle invasive bladder cancer based on whole transcriptome analysis

By: Shen J.2, Noon A.3, Aguiar Cabeza E.2, Kuk C.4, Ilczynski C.5, Ni R.5, Sukhu B.5, Chan K.2, Gunaratne A.2, Erlich A.4, Cremer C.6, Morris Q.6, Barbosa-Morais N.6, Roupret M.9, Compérat E.10, Sweet J.8, Fleshner N.7, Kulkarni G.7, Blencowe B.6, Azad A.5, Van Der Kwast T.8, Zlotta A.R.1, Wrana J.2

Institutes: 1Mount Sinai Hospital & Princess Margaret Cancer Centre, Dept. of Urology, Toronto, Canada, 2Mount Sinai Hospital, Lunenfeld-Tanenbaum Research Institute, Toronto, Canada, 3University of Sheffield, Dept. of Urology, Sheffield, United Kingdom, 4Mount Sinai Hospital, Dept. of Urology, Toronto, Canada, 5Mount Sinai Hospital, Dept. of Pathology and Laboratory Medicine, Toronto, Canada, 6University of Toronto, Terrence Donnelly Centre for Cellular and Biomolecular Research, Toronto, Canada, 7Princess Margaret Cancer Centre, Dept. of Surgical Oncology, Division of Urology, University Health Network, Toronto, Canada, 8University Health Network, Dept. of Pathology, Toronto, Canada, 9Group Hospitalier La Pitié-Salpêtière, Université Pierre et Marie Curie, Dept. of Urology, Paris, France, 10Group Hospitalier La Pitié-Salpêtière, Université Pierre et Marie Curie, Dept. of Pathology, Paris, France

747
Bladder cancer and seroreactivity to BK, JC and Merkel cell polyomaviruses: The Spanish bladder cancer study

By: Garcia-Rojo D.1, Robles C.2, Viscidi R.3, Malats N.4, Silverman D.5, Gelabert-Mas A.6, Ibarz L.7, Cecchini L.6, Kogevinas M.8, Garcia-Closas R.9, Prera A.1, Lloreta J.10, Consol S.11, Carrato A.12, Abascal R.13, Fernandez J.M.13, Rodriguez De Vera J.M.14, Rivas M.15, Guate J.L.16, Malet J.M.17, Muntañola P.18, Gonzalez-Huergo J.19, Mosquera J.20, Cespedes M.21, Prats J.22, Real F.X.23

Institutes: 1Consorci Hospitalari Parc Tauli, Dept. of Urology, Sabadell, Spain, 2Catalan Institute of Oncology, Dept. of Infections and Cancer, Hospitalet De Llobregat, Spain, 3Johns Hopkins University School of Medicine, Stanley Division of Developmental Neurovirology, Baltimore, United States of America, 4Spanish National Cancer Research Centre (CNIO), Dept. of Genetic and Molecular Epidemiology, Madrid, Spain, 5National Cancer Institute, De[t. of Cancer Epidemiology and Genetics, Bethesda, United States of America, 6Hospital Del Mar, Dept. of Urology, Barcelona, Spain, 7Hospital Germans Trias I Pujol, Dept. of Urology, Badalona, Spain, 8IMIM, Dept. of Epidemiology, Barcelona, Spain, 9Hospital Universitario Canarias, Dept. of Epidemiology, Barcelona, Spain, 10Hospital Del Mar, Dept. of Pathology, Barcelona, Spain, 11Consorci Hospitalari Parc Tauli, Dept. of Epidemiology, Sabadell, Spain, 12Hospital Elche, Dept. of Oncology, Elche, Spain, 13Hospital Central De Asturias, Dept. of Urology, Oviedo, Spain, 14Hospital Universitario De Canarias, Dept. of Urology, Santa Cruz de Tenerife, Spain, 15Hospital Cabueñes, Dept. of Urology, Cabueñes, Spain, 16Hospital Aviles, Dept. of Urology, Aviles, Spain, 17Hospital Manresa, Dept. of Urology, Manresa, Spain, 18Hospital Mieres, Dept. of Urology, Mieres, Spain, 19Hospital Coaña, Dept. of Urology, Coaña, Spain, 20Hospital Cangas, Dept. of Urology, Cangas, Spain, 21Hospital Sant Boi, Dept. of Urology, Sant Boi De Llolbregat, Spain, 22Corporacio Parc Tauli, Dept. of Urology, Sabadell, Spain, 23Spanish National Cancer Research Centre (CNIO), Genetic and Molecular Epidemiology Group, Madrid, Spain

749
Diagnostic utility of UroVysion for urothelial carcinoma of the upper urinary tract

By: Sassa N.1, Tsuzuki T.2, Hattori R.3, Kato M.1, Ishida S.1, Sano T.3, Gotoh M.1

Institutes: 1Nagoya University, Dept. of Urology, Nagoya, Japan, 2Japanese Red Cross Nagoya Daini Hospital, Dept. of Pathology, Nagoya, Japan, 3Japanese Red Cross Nagoya Daiichi Hospital, Dept. of Urology, Nagoya, Japan

750
Detection of carcinoma in situ (CIS) of urinary bladder cancer using UBC® Rapid as tumour marker

By: Ecke T.1, Arndt C.2, Gützlaff S.3, Stephan C.3, Lux O.1, Otto T.2, Hallmann S.1, Ruttloff J.1, Gerullis H.4

Institutes: 1Helios Hospital, Dept. of Urology, Bad Saarow, Germany, 2Lukaskrankenhaus, Dept. of Urology, Neuss, Germany, 3University Hospital Charité, Dept. of Urology, Berlin, Germany, 4University Oldenburg, Dept. of Urology, Oldenburg, Germany

751
Colour and morphology combination for detection of low-grade urothelial cancer cells: Multi-center validation study

By: Yossepowitch O.1, Leibovitch I.4, Nativ O.5, Cohen M.11, Mor Y.6, Lindner U.7, Sidi A.10, Matzkin H.9, Gofrit O.8, Rona R.12, Shtabsky A.2, Lew S.3

Institutes: 1Rabin Medical Center, Dept. of Urology, Petach Tikva, Israel, 2Sourasky Medical Center, Dept. of Pathology, Tel-Aviv, Israel, 3Patho-Lab Diagnostics Ltd, Dept. of Pathology, Ness Ziona, Israel, 4Meir Medical Center, Dept. of Urology, Kfar Saba, Israel, 5Bnai Zion Medical Center, Dept. of Urology, Haifa, Israel, 6Sheba Medical Center, Dept. of Urology, Tel-Aviv, Israel, 7Kaplan Medical Center, Dept. of Urology, Rehovot, Israel, 8Hadassah Medical Center, Dept. of Urology, Jerusalem, Israel, 9Sourasky Medical Center, Dept. of Urology, Tel-Aviv, Israel, 10Wolfson Medical Center, Dept. of Urology, Holon, Israel, 11HaEmek Medical Center, Dept. of Urology, Afula, Israel, 12Meir Medical Center, Dept. of Pathology, Kfar Saba, Israel